Oncternal Therapeutics Inc (NAS:ONCT)
$ 0.5266 0 (0%) Market Cap: 1.56 Mil Enterprise Value: -12.83 Mil PE Ratio: 0 PB Ratio: 0.17 GF Score: 29/100

Q4 2022 Oncternal Therapeutics Inc Earnings Call Transcript

Mar 09, 2023 / 10:00PM GMT
Release Date Price: $17.72 (-0.56%)
Operator

Greetings, and welcome to the Oncternal Therapeutics, Inc. fourth-quarter 2022 financial results conference call. (Operator Instructions) And as a reminder, this conference is being recorded. It is now my pleasure to introduce to you to Richard Vincent, CFO. Thank you, Richard, you may begin.

Richard Vincent
Oncternal Therapeutics, Inc. - CFO

Thank you, John. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our President and CEO, Dr. James Breitmeyer; and our CMO, Dr. Salim Yazji. Today's call includes a business update and discussion of our results for the fourth quarter and full year 2022, which will be followed by Q&A. Today's press release and a replay of today's call will be available on the Investor Relations section of Oncternal's website for at least the next 30 days. We filed our 10-K for the full year 2022 earlier today.

Please note that certain information discussed on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot